Straight Talk Wireless has enhanced its Silver, Gold, and Platinum Unlimited plans by offering faster 5G Ultra Wideband speeds, increased hotspot data by up to 66%, expanded international coverage, and new Home Internet bundle savings—all without raising monthly base prices. The Silver Unlimited plan remains at $45/month, now with 15 GB hotspot data and international talk/text to select countries. Gold and Platinum plans include even more data, Walmart+ memberships, cloud storage, and tablet service benefits. These upgrades aim to provide more value to cost-conscious consumers while keeping prices stable, reinforcing Straight Talk's commitment to affordable, high-quality wireless service.
Straight Talk Wireless enhancements offer faster 5G and more data. For readers following the Technology sector, here is Pluang's market snapshot as of Oct 19, 2026 19:31 WIB: 93 of 150 US tech stocks rose today. Notable gainers include CRDO at USD 177.83 (+4.79%), CRSR at USD 13.40 (+4.77%), and MRVL at USD 238.15 (+4.53%).
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
